The table below shows BioNexus Gene Lab Corp's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$147.67K
-$824.07K
-$37.15K
-$116.52K
-$37.84K
$115.43K
Capital expenditure
$325.00
$9.05K
$21.95K
$102.00
$32.19K
$807.00
Investing cash flow
-$13.99K
-$15.65K
$3.65K
-$5.06K
-$197.13K
-$295.83K
Dividends paid
-
-
-
BGLC operating cash flow (10-K history)
BioNexus Gene Lab Corp reported operating cash flow of -$1.84M for fiscal year 2025. That is up 12.2% from -$2.09M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$274.08K (FY 2018) to -$1.84M. Figures come from the company's audited annual reports as filed with the SEC.